as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹821.95
Change
+1.35 (0.16%)
Open
₹818.5
Prev. Close
₹820.6
Day High
₹827.95
Day Low
₹802.2
Volume Analysis
Traded
735,748
Delivered
372,538
Delivery %
50.63%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (24.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (1)
- •Strong 3-year EPS growth (26.4%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹858.29 | ₹843.12 | ₹832.54 | ₹817.37 | ₹806.79 | ₹791.62 | ₹781.04 |
| Fibonacci | ₹843.12 | ₹833.28 | ₹827.21 | ₹817.37 | ₹807.53 | ₹801.46 | ₹791.62 |
| Camarilla | ₹829.03 | ₹826.67 | ₹824.31 | ₹817.37 | ₹819.59 | ₹817.23 | ₹814.87 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-7.46%
1 Week
+1.63%
1 Month
+4.78%
3 Months
-6.85%
6 Months
-29.73%
1 Year
-5.45%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹977.77
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.37%
Net margin 26.84% × asset turnover 0.35x × equity multiplier 1.21x
Company Overview
Sector
Healthcare
Market Cap
₹15,881 Cr
P/E (TTM)
19.1
ROE
17.1%
Book Value
₹541.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Natco Pharma Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Momentum (8/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (24.0%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 28.1% CAGR over last 5 years
- −Promoter holding has decreased over last quarter: -3.19%
- −Tax rate seems low
- −Earnings include an other income of Rs.247 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
NATCO filed Q2 FY27 earnings call transcript; revenue ₹1,019.4 crore, PAT ₹202.6 crore, FY27 PAT guided ₹775–800 crore.
Newspaper publication for Unaudited Financail Results for the Qaurter and Half year ended September 30, 2026 and Record date for the 2nd Interim Dividend for …
Audio link shared for Q2 FY27 earnings conference call held on 13 November 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 | 967 |
| Expenses + | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 | 709 |
| Operating Profit | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 | 258 |
| OPM % | 44.0% | 35.0% | 47.0% | 59.0% | 59.0% | 8.0% | 45.0% | 43.0% | 42.0% | 25.0% | 17.0% | 25.0% | 27.0% |
| Other Income + | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 | 52 |
| Interest | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 | 18 |
| Depreciation | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 | 49 |
| Profit before tax | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 | 243 |
| Tax % | 16.0% | 17.0% | 19.0% | 17.0% | 17.0% | 19.0% | 20.0% | 16.0% | 16.0% | 13.0% | -62.0% | 34.0% | 29.0% |
| Net Profit + | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 | 203 |
| EPS in Rs | 20 | 12 | 21 | 37 | 38 | 7 | 23 | 27 | 29 | 8 | 15 | 11 | 11 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 139 | 54 | 19 | 19 | 33 | -37 | 14 | -2 | -1 | 36 | -39 | -45 | -29 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 825 | 1,042 | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 | 3,089 |
| Expenses + | 615 | 777 | 1,337 | 1,256 | 1,300 | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 | 2,234 | 2,617 | 2,358 |
| Operating Profit | 210 | 266 | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,196 | 1,462 | 731 |
| OPM % | 25.0% | 25.0% | 34.0% | 42.0% | 38.0% | 30.0% | 30.0% | 14.0% | 35.0% | 44.0% | 50.0% | 36.0% | 24.0% |
| Other Income + | 0 | 12 | 14 | 40 | 130 | 107 | 104 | 99 | 105 | 126 | 354 | 272 | 247 |
| Interest | 32 | 23 | 18 | 15 | 19 | 22 | 13 | 18 | 14 | 19 | 24 | 37 | 51 |
| Depreciation | 47 | 51 | 54 | 66 | 81 | 100 | 117 | 143 | 164 | 187 | 235 | 207 | 193 |
| Profit before tax | 132 | 204 | 624 | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 | 734 |
| Tax % | 1.0% | 24.0% | 22.0% | 22.0% | 22.0% | 19.0% | 24.0% | 16.0% | 17.0% | 17.0% | 18.0% | 8.0% | — |
| Net Profit + | 130 | 156 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,418 | 829 |
| EPS in Rs | 8 | 9 | 28 | 37 | 35 | 25 | 24 | 9 | 39 | 77 | 104 | 79 | 46 |
| Dividend Payout % | 12.0% | 14.0% | 24.0% | 22.0% | 18.0% | 27.0% | 22.0% | 48.0% | 14.0% | 12.0% | 6.0% | 6.0% | — |
| Sales growth | 12 | 26 | 94 | 8 | -4 | -9 | 7 | -5 | 39 | 48 | 11 | -8 | -30 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 813 | 1,261 | 1,614 | 3,035 | 3,452 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 | 7,571 | 9,185 | 9,729 |
| Borrowings + | 312 | 113 | 222 | 173 | 386 | 316 | 268 | 416 | 167 | 371 | 279 | 714 | 1,033 |
| Other Liabilities + | 226 | 413 | 446 | 470 | 428 | 498 | 403 | 430 | 617 | 682 | 744 | 1,138 | 1,001 |
| Total Liabilities | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 | 11,799 |
| Fixed Assets + | 710 | 710 | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 | 2,698 | 2,803 | 2,846 |
| CWIP | 129 | 212 | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 | 225 | 294 | 396 |
| Investments | 2 | 22 | 32 | 76 | 169 | 112 | 304 | 308 | 392 | 539 | 474 | 3,127 | 4,417 |
| Other Assets + | 543 | 878 | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 | 5,234 | 4,850 | 4,140 |
| Total Assets | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 | 11,799 |
| Equity Capital | 33 | 35 | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 93 | 112 | 346 | 464 | 669 | 417 | 299 | 46 | 849 | 1,212 | 1,697 | 1,768 |
| Cash from Investing Activity + | -120 | -176 | -299 | -1,116 | -611 | -175 | -107 | 4 | -465 | -1,026 | -1,436 | -1,987 |
| Cash from Financing Activity + | 29 | 154 | -48 | 651 | -51 | -251 | -186 | 35 | -363 | -247 | -211 | 298 |
| Net Cash Flow | 2 | 90 | -1 | -2 | 7 | -8 | 6 | 85 | 21 | -62 | 50 | 79 |
| Free Cash Flow | -25 | -44 | 66 | 57 | 225 | 81 | 92 | -142 | 674 | 855 | 1,300 | 1,379 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 55 | 60 | 69 | 72 | 107 | 90 | 71 | 36 | 110 | 85 | 94 | 148 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Oct 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 24.46% | 24.99% | 26.13% | 26.88% | 27.3% | 29.12% | 30.56% | 29.97% | 27.74% | 27.97% | 28.46% | 27.59% |
| Promoters | 49.71% | 49.71% | 49.62% | 49.62% | 49.56% | 49.56% | 49.48% | 49.48% | 49.41% | 49.41% | 49.39% | 46.22% |
| FII | 16.14% | 17.45% | 17.51% | 17.94% | 17.49% | 15.52% | 14.09% | 15.16% | 17.37% | 16.99% | 15.99% | 15.37% |
| DII | 9.69% | 7.86% | 6.75% | 5.59% | 5.64% | 5.81% | 5.87% | 5.39% | 5.46% | 5.63% | 6.16% | 10.82% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Natco Pharma Ltd. (this stock) | 15,881 | 19.1 | 1.5 | 17.1% |
| Indegene Limited | 15,640 | 36.7 | 4.67 | 14.4% |
| Jubilant Pharmova Ltd | 14,883 | 50.4 | 2.08 | 6.53% |
| Poly Medicure Limited | 17,041 | 53.9 | 5.22 | 9.8% |
| Molbio Diagnostics Ltd | 17,111 | 236.0 | 11.89 | 15.6% |
| Vijaya Diagnostic Cen Ltd | 14,524 | 71.3 | 13.69 | 18.9% |
| Dr Agarwals Health Care L | 17,460 | 97.5 | 7.8 | 6.41% |
Which Mutual Funds Hold Natco Pharma Ltd.?
Frequently Asked Questions about Natco Pharma Ltd.
Natco Pharma Ltd. (NATCOPHARM) closed at ₹821.95 on NSE on 19 November 2026, up 1.35 (0.16%) from the previous close.
Natco Pharma Ltd. trades on the NSE (National Stock Exchange of India) under the symbol NATCOPHARM.
Natco Pharma Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 19.1.
Natco Pharma Ltd. has a dividend yield of 0.62%.
Natco Pharma Ltd.'s 52-week high is ₹1,217.0 and its 52-week low is ₹774.0.
Natco Pharma Ltd. has a market capitalisation of ₹15,881 crore.
Natco Pharma Ltd. has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Natco Pharma Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.